I am a
Home I AM A Search Login

Papers of the Week

2022 Sep 12

J Allergy Clin Immunol Pract

Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.


Reich K, Lio PA, Bissonnette R, Alexis AF, Lebwohl MG, Pink AE, Kabashima K, Boguniewicz M, Nowicki RJ, Valdez H, Zhang F, DiBonaventura M, Cameron MC, Clibborn C
J Allergy Clin Immunol Pract. 2022 Sep 12.
PMID: 36108923.


Emerging treatments for moderate-to-severe atopic dermatitis (AD) may provide greater and faster improvement in AD signs and symptoms than current therapies.